Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:EQ

Equillium Q4 2025 Earnings Report

Equillium logo
$2.17 +0.10 (+4.83%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$2.12 -0.05 (-2.53%)
As of 05/6/2026 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Equillium EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.07
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Equillium Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Equillium Announcement Details

Quarter
Q4 2025
Date
3/25/2026
Time
After Market Closes
Conference Call Date
Monday, March 30, 2026
Conference Call Time
12:30PM ET

Upcoming Earnings

Equillium's Q1 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Equillium's Q4 2025 Annual reportAnnual report
(10-K)

Equillium Earnings Headlines

Equillium, Inc. Grants Inducement Stock Options to New Employees Under 2024 Inducement Plan
May 1, 2026  |  quiverquant.comQ
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286233/0/en/equillium-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
 |  American Alternative (Ad)
Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282815/0/en/equiniti-eq-launches-dealtrax-a-digital-first-platform-for-corporate-actions-and-m-a-events.html
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
April 20, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/equillium-to-participate-in-oppenheimer-s-2026-innovation-on-the-island-event-1036039558
Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3277456/0/en/equillium-to-participate-in-oppenheimer-s-2026-innovation-on-the-island-event.html
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ) (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies. The company has since advanced EQ001 through Phase 1 and Phase 2 clinical trials, evaluating its potential in steroid-refractory acute GVHD and exploring additional autoimmune indications, such as ulcerative colitis. Equillium’s R&D strategy emphasizes rigorous clinical development and targeted patient populations to address areas of high unmet medical need.

Equillium conducts its clinical trials and research activities primarily in the United States, collaborating with leading academic institutions and transplant centers. The company’s global development plan includes potential partnerships or licensing arrangements to expand access to its therapies beyond North America. Equillium maintains a focused corporate structure designed to streamline decision-making and support efficient execution of its clinical programs.

Under the leadership of President and Chief Executive Officer Roger Pomerantz, Equillium has built a management team with deep expertise in immunology, clinical development, and regulatory affairs. The company’s board and scientific advisory committee include seasoned industry professionals who guide Equillium’s strategic direction. As a clinical-stage enterprise, Equillium remains committed to advancing its immunotherapy candidates through pivotal trials and towards regulatory approval for patients in need.

View Equillium Profile
Earnings Tools